Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 4 | -$0.51 | -$0.34 | -$0.43 |
Q2 2025 | 2 | $0.20 | $0.20 | $0.20 |
Q3 2025 | 2 | -$0.18 | -$0.18 | -$0.18 |
Q4 2025 | 3 | $0.26 | $0.26 | $0.26 |
Q1 2026 | 2 | $0.22 | $0.22 | $0.22 |
Q2 2026 | 1 | -$0.62 | -$0.62 | -$0.62 |
Q3 2026 | 1 | -$0.10 | -$0.10 | -$0.10 |
Q4 2026 | 2 | $0.60 | $0.60 | $0.60 |
Novavax, Inc. last posted its earnings results on Thursday, February 27th, 2025. The company reported $-0.51 earnings per share for the quarter, topping analysts' consensus estimates of $-0.75 by $0.24. The company had revenue of 88.31 M for the quarter and had revenue of 682.16 M for the year. Novavax, Inc. has generated $-1 earnings per share over the last year ($-1.23 diluted earnings per share) and currently has a price-to-earnings ratio of -4.51. Novavax, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 8th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
02/27/2025 | Q4 2024 | -$0.75 | -$0.51 | 0.24 | $84.38 M | $88.31 M |
11/12/2024 | Q3 2024 | -$0.87 | -$0.76 | 0.11 | $73.78 M | $84.51 M |
08/08/2024 | Q2 2024 | $1.64 | $1.11 | -0.53 | $458.58 M | $415.48 M |
05/10/2024 | Q1 2024 | -$1.04 | -$1.05 | -0.01 | $101.16 M | $93.86 M |
02/28/2024 | Q4 2023 | -$0.49 | -$1.44 | -0.95 | $322.05 M | $291.34 M |
11/09/2023 | Q3 2023 | -$1.82 | -$1.26 | 0.56 | $115.42 M | $22.06 M |
08/08/2023 | Q2 2023 | -$1.39 | $0.65 | 2.04 | $264.16 M | $424.43 M |
05/09/2023 | Q1 2023 | -$3.38 | -$3.41 | -0.03 | N/A | $80.95 M |
02/28/2023 | Q4 2022 | -$0.92 | -$2.28 | -1.36 | N/A | $287.83 M |
11/09/2022 | Q3 2022 | N/A | -$2.15 | N/A | $586.25 M | $734.58 M |
08/08/2022 | Q2 2022 | N/A | -$6.53 | N/A | $863.68 M | $185.93 M |
05/09/2022 | Q1 2022 | N/A | $2.56 | N/A | N/A | $703.97 M |
02/28/2022 | Q4 2021 | N/A | -$11.18 | N/A | N/A | $222.20 M |
11/04/2021 | Q3 2021 | N/A | -$4.31 | N/A | $334.53 M | $178.84 M |
08/05/2021 | Q2 2021 | -$3.76 | -$4.75 | -0.99 | $387.87 M | $298.02 M |
05/10/2021 | Q1 2021 | -$2.65 | -$3.05 | -0.4 | N/A | $447.23 M |
03/01/2021 | Q4 2020 | -$1.53 | -$2.70 | -1.17 | N/A | $279.66 M |
11/10/2020 | Q3 2020 | N/A | -$3.21 | N/A | $230.56 M | $157.02 M |
08/10/2020 | Q2 2020 | -$0.57 | -$0.30 | 0.27 | $28.20 M | $35.54 M |
05/11/2020 | Q1 2020 | -$0.67 | -$0.58 | 0.09 | N/A | $3.38 M |
Novavax, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 8th, 2025 based offlast year's report dates.
In the previous quarter, Novavax, Inc. (:NVAX) reported $-0.51 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.75 by $0.24.
The conference call for Novavax, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Novavax, Inc.'s latest earnings report can be read online.
Novavax, Inc. (:NVAX) has a recorded annual revenue of $682.16 M.
Novavax, Inc. (:NVAX) has a recorded net income of $-187,499,000.Novavax, Inc. has generated $-1.23 earnings per share over the last four quarters.
Novavax, Inc. (:NVAX) has a price-to-earnings ratio of -4.51 and price/earnings-to-growth ratio is -0.1.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED